Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

11000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the purpose of this study is to determine whether calcium supplementation is effective to prevent preeclampsia in Sichuang Province of china and which dose is more suitable

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low Dose Calcium to Prevent Preeclampsia

NCT02338687

Pre-Eclampsia Hypertension, Pregnancy-Induced Dietary Calcium Deficiency

COMPLETED PHASE4

Oral Calcium in Pregnant Women With Hypertension

NCT00000543

Cardiovascular Diseases Heart Diseases Hypertension +3 more

COMPLETED PHASE2

Calcium for Pre-Eclampsia Prevention (CPEP)

NCT00000534

Cardiovascular Diseases Eclampsia Heart Diseases +5 more

COMPLETED PHASE3

Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China

NCT01804751

Preeclampsia

UNKNOWN

The Association Between Parathyroid Hormone and Preterm Labor

NCT05688007

Preterm Labor Parathyroid Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

calcium A

tablets, 600mg per day,till birth

Group Type ACTIVE_COMPARATOR

calcium

Intervention Type DRUG

calcium B

tablets,1200mg per day,till birth

Group Type ACTIVE_COMPARATOR

calcium

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

calcium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Nulliparity;age ≥35 years;Previous pre-eclampsia;Family history of pre-eclampsia;Multiple pregnancy;Time between pregnancies ≥10years;Body mass index ≥25;diastolic pressure ≥ 80 mm Hg before 20 weeks' gestation;Proteinuria ≥+ on more than one occasion or ≥ 300 mg/24 h before 20 weeks' gestation;Underlying medical conditions(Pre-existing hypertension;Pre-existing renal disease;Pre-existing diabetes;Presence of antiphospholipid antibodies;Chronic autoimmune disease);male sex partner's predecessor wife has Previous pre-eclampsia

Exclusion Criteria

* first prenatal visit after 16 weeks' gestation;severe anemia;other Underlying medical conditions which need treatment first (such as uncontrolled hyperthyreosis )

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No